lupus Lupus Research Alliance Applauds U.S. FDA Fast Track Designationの詳細情報
Lupus Research Alliance Applauds U.S. FDA Fast Track Designation。Genetic susceptibility to systemic lupus erythematosus in the。Phase 2 Safety and Efficacy of Subcutaneous (s.c.) Dose Ianalumab。Evolving concepts in systemic lupus erythematosus damage。種別...シングルカード 1枚